interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Letrozole; Ribociclib Succinate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Letrozole; Ribociclib Succinate, and who makes it?

Letrozole; Ribociclib Succinate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Letrozole; Ribociclib Succinate1 dosage-form group in the Orange Book
0generic makers listed
  1. Letrozole; Ribociclib Succinate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Kisqali Femara Co-Pack (Copackaged). No generic is listed as marketed.

20152020202520302035204001brand 2017data datePatent 8324225 listed to expire 17 June 2028Patent 8324225*PED listed to expire 17 December 2028Patent 9416136 listed to expire 20 August 2029Patent 8962630 listed to expire 9 December 2029Patent 9416136*PED listed to expire 20 February 2030Patent 8685980 listed to expire 25 May 2030Patent 8962630*PED listed to expire 9 June 2030Patent 8685980*PED listed to expire 25 November 2030Patent 8415355 listed to expire 13 March 2031Patent 8415355*PED listed to expire 13 September 2031Patent 9868739 listed to expire 9 November 2031Patent 9193732 listed to expire 9 November 2031Patent 9193732*PED listed to expire 9 May 2032Patent 9868739*PED listed to expire 9 May 2032Patent 12544380 listed to expire 7 August 2034Patent 12544380*PED listed to expire 7 February 2035Patent 12419894 listed to expire 14 April 2036Patent 10799506 listed to expire 14 April 2036Patent 12064434 listed to expire 14 April 2036Patent 10799506*PED listed to expire 14 October 2036Patent 12064434*PED listed to expire 14 October 2036Patent 12419894*PED listed to expire 14 October 2036Exclusivity I-951 to 17 September 2027Exclusivity PED to 17 March 2028Exclusivity M-14 to 1 July 2029Exclusivity PED to 1 January 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 17 September 2027Exclusivity I-951 Kisqali Femara Co-Pack (Copackaged)
  • 17 March 2028Exclusivity PED Kisqali Femara Co-Pack (Copackaged)
  • 1 July 2029Exclusivity M-14 Kisqali Femara Co-Pack (Copackaged)
  • 1 January 2030Exclusivity PED Kisqali Femara Co-Pack (Copackaged)
  • 17 June 2028Patent 8324225 drug substance
  • 17 December 2028Patent 8324225*PED
  • 20 August 2029Patent 9416136
  • 9 December 2029Patent 8962630
  • 20 February 2030Patent 9416136*PED
  • 25 May 2030Patent 8685980 drug substance
  • 9 June 2030Patent 8962630*PED
  • 25 November 2030Patent 8685980*PED

14 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.